jim_asheville said:The shortage clause is the answer to the second question and it is a subtraction rather than an addition.
Saving this. It is the first explanation that did not require me to already understand it.
From the other side of the consultation, briefly.
Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.
Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide shortage ongoing, tirzepatide partially resolved. This directly impacts compounding availability.
Dr.RaviCardio said:The trade-off is reversibility against privacy and there is no option that gives you both.
Compounding pharmacy customer here with experience relevant to compounded supply.
I've ordered from 5 different compounding pharmacies over the past 18 months. The quality variation is real — purity ranged from 94% to 101% of label claim based on independent Janoshik testing.
My current compounder (a 503B facility) has been consistently 98-101% purity across 5 orders. I pay $120/month vs $1,390 for brand. The savings are substantial and the product is equivalent in my experience.
Re: compounded supply — this applies whether you're using brand or compounded. The clinical principles are the same.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsDr.SurgeonPGH said:They are two different exemptions from the same federal requirements and they buy different things.
For compounded supply users considering compounded for the first time: here's a step-by-step guide:
Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Report rather than reply if it drifts again.